Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
Maravai LifeSciences Holdings
MRVI
Maravai LifeSciences Holdings
Rising Regulatory Burdens Will Weaken mRNA Base Despite BST Gains
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
07 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$2.00
21.0% overvalued
intrinsic discount
16 Aug
US$2.42
1Y
-73.2%
7D
-3.6%
Loading
1Y
-73.2%
7D
-3.6%
Author's Valuation
US$2.0
21.0% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$2.0
21.0% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-193m
920m
2018
2020
2022
2024
2025
2026
2028
Revenue US$124.2m
Earnings US$15.9m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
4.02%
Life Sciences revenue growth rate
0.32%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.34%
Calculation
US$15.90m
Earnings '28
x
24.37x
PE Ratio '28
=
US$387.46m
Market Cap '28
US$387.46m
Market Cap '28
/
152.59m
No. shares '28
=
US$2.54
Share Price '28
US$2.54
Share Price '28
Discounted to 2025 @ 8.28% p.a.
=
US$2.00
Fair Value '25